CN115867542A - 新型苯并咪唑化合物 - Google Patents

新型苯并咪唑化合物 Download PDF

Info

Publication number
CN115867542A
CN115867542A CN202180046799.6A CN202180046799A CN115867542A CN 115867542 A CN115867542 A CN 115867542A CN 202180046799 A CN202180046799 A CN 202180046799A CN 115867542 A CN115867542 A CN 115867542A
Authority
CN
China
Prior art keywords
membered
heterocycloalkyl
alkyl
pharmaceutically acceptable
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180046799.6A
Other languages
English (en)
Inventor
谢雨礼
吴应鸣
钱立晖
樊后兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of CN115867542A publication Critical patent/CN115867542A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Abstract

本发明涉及一种通式(1)所示的化合物及其制备方法，及通式(1)化合物及其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物作为EGFR抑制剂在抗肿瘤等EGFR相关疾病的药物制备中的用途。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN202180046799.6A 2020-07-01 2021-06-30 新型苯并咪唑化合物 Pending CN115867542A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010629495.XA CN113880804A (zh) 2020-07-01 2020-07-01 新型苯并咪唑化合物
CN202010629495X 2020-07-01
PCT/CN2021/103366 WO2022002100A1 (zh) 2020-07-01 2021-06-30 新型苯并咪唑化合物

Publications (1)

Publication Number Publication Date
CN115867542A true CN115867542A (zh) 2023-03-28

Family

ID=79012998

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010629495.XA Pending CN113880804A (zh) 2020-07-01 2020-07-01 新型苯并咪唑化合物
CN202180046799.6A Pending CN115867542A (zh) 2020-07-01 2021-06-30 新型苯并咪唑化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010629495.XA Pending CN113880804A (zh) 2020-07-01 2020-07-01 新型苯并咪唑化合物

Country Status (2)

Country Link
CN (2) CN113880804A (zh)
WO (1) WO2022002100A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379575A (zh) * 2012-06-06 2015-02-25 Irm责任有限公司 用于调节egfr活性的化合物和组合物
WO2019162323A1 (en) * 2018-02-21 2019-08-29 Boehringer Ingelheim International Gmbh New benzimidazole compounds and derivatives as egfr inhibitors
CN114007698A (zh) * 2019-06-24 2022-02-01 勃林格殷格翰国际有限公司 作为egfr抑制剂的新型大环化合物和衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379575A (zh) * 2012-06-06 2015-02-25 Irm责任有限公司 用于调节egfr活性的化合物和组合物
WO2019162323A1 (en) * 2018-02-21 2019-08-29 Boehringer Ingelheim International Gmbh New benzimidazole compounds and derivatives as egfr inhibitors
CN114007698A (zh) * 2019-06-24 2022-02-01 勃林格殷格翰国际有限公司 作为egfr抑制剂的新型大环化合物和衍生物

Also Published As

Publication number Publication date
CN113880804A (zh) 2022-01-04
WO2022002100A1 (zh) 2022-01-06

Similar Documents

Publication Publication Date Title
CN115335379B (zh) 含螺环的喹唑啉化合物
CN113544128B (zh) Kras-g12c抑制剂
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
CN111499634B (zh) 一种喹唑啉化合物及其在医药上的应用
CN116390728B (zh) 喹唑啉衍生物及其制备方法和用途
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN115785068A (zh) Kif18a抑制剂
CN115867542A (zh) 新型苯并咪唑化合物
WO2022012593A1 (zh) 5，6-二氢吡嗪并[2，3-c]异喹啉化合物
EP4159731A1 (en) New pyrazine compound
WO2022228512A1 (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
WO2022228511A1 (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
CN117412971A (zh) 含吡嗪结构的吡咯并嘧啶衍生物
CN117500813A (zh) 芳基氧膦类化合物
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
WO2022228509A1 (zh) 吡咯并嘧啶衍生物及其制备方法和用途
WO2023134608A1 (zh) 作为hpk1抑制剂的稠环化合物
WO2023083299A1 (zh) 作为hpk1抑制剂的稠环化合物
WO2023143344A1 (zh) 新型egfr抑制剂
WO2023045942A1 (zh) 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2022171128A1 (zh) 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
TW202306955A (zh) 作為atr抑制劑的萘啶衍生物及其製備方法
EP4296268A1 (en) Pyrimidine compound as wee-1 inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination